Pathway Therapeutics
About:
Pathway Therapeutics develops selective inhibitors of PI3-kinase for the treatment of cancer and inflammatory diseases.
Website: http://pathwaytx.com
Top Investors: GBS Ventures, New Zealand Venture Investment Fund, Talu Ventures
Description:
Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.
Total Funding Amount:
$24.4M
Headquarters Location:
San Francisco, California, United States
Founded Date:
2008-01-01
Contact Email:
info(AT)pathwaytx.com
Founders:
Julie Cherrington
Number of Employees:
11-50
Last Funding Date:
2013-03-05
IPO Status:
Private
Industries:
© 2025 bioDAO.ai